Opus Genetics, Inc. (NASDAQ: IRD) CEO Magrath George exercised options for 392,157 shares at $1.15 per share on 9 September 2026. The exercise represented about 18.5% of his resulting share holding, which stood at 2,124,026 shares afterward.
Park Ha Biological Technology Co. Ltd. (NASDAQ: BYAH) raised approximately US $2,970,000 through a privatePlacementthat sold 1,080,000 Class A ordinary shares at $2.75 per share. The transaction also provides participating non-U.S. Investors with warrants covering 1,845,452 Class A ordinary shares.
Pharming Group N.V. (NASDAQ: PHAR) received U.S. FDA approval expanding Joenja’s use to children ages 4 to 11 with activated phosphoinositide 3-kinaseDeltasyndrome, or APDS, who weigh at least 27 kg.
Kailera Therapeutics, Inc. (NASDAQ:KLRA) has become one of the more closely followed newcomers in the obesity-drug arms race, and its shares closed down 6.51% at $13.94 at last closing. For a clinical-stage biotech that only recently went public, sharp daily swings are par for …
SCYNEXIS INC (NASDAQ: SCYX) awarded Chief Financial Officer Subramanian Sanjay 100,000 derivative securities on Sep 9. The transaction left him with 100,000 derivative securities, according to the reported insider transaction.
Micro-cap biotech stocks can lurch on the thinnest of volumes, and Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a textbook example. Shares closed up 8.29% at $2.22 at last closing, a jump that has drawn eyes to this obscure name, but the story is less about …
Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) is reported as beneficially owned at 54.6% by Celadon Partners SPV 24, Celadon Partners, LLC and CPIF II-7 Limited. The reported position covers 25,748,890 shares of common stock and is identified as activist under Schedule 13D. The position …
Few 2026 biotech debutants have arrived with as much momentum as Latigo Biotherapeutics. The non-opioid pain developer priced one of the year's larger clinical-stage offerings in August, drew a wall of bullish analyst coverage within weeks, and now commands aMarket Valuewell above a billion …
A gain in one of 2026's higher-profile biotech IPOs put Veradermics, Incorporated (NYSE:MANE) back in focus in September 2026, as the hair-loss specialist closed up 0.85% at $98.97 at last closing. The move was modest in percentage terms but notable given the company's multibillion-dollar …
Medline Inc. (NASDAQ:MDLN) arrived on the public markets late in 2025 as one of the largest healthcare listings in years, giving investors a rare pure-play stake in the medical-supply backbone of hospitals and care facilities. Nearly a year on, shares closed up 0.43% at …